Abacavir: it’s use and hypersensitivity

Abacavir: it’s use and hypersensitivity

Abacavir, a nucleoside reverse transcriptase inhibitor, is useful in first and second line therapy as well as a substitute for Stavudine and Zidovudine for toxicity. Although safe and well tolerated, a life threatening hypersensitivity reaction can occur. The risk for developing this reaction relate...

Full description

Bibliographic Details
Main Authors:	Helena Rabie, Kristin Lorenc Henning, Pierre Schoeman, Nico de Villiers, G HJ Pretorius, Mark F Cotton
Format:	Article
Language:	English
Published:	AOSIS 2009-12-01
Series:	Southern African Journal of HIV Medicine
Online Access:	https://sajhivmed.org.za/index.php/hivmed/article/view/265

Similar Items

The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome
by: James Fodor, et al.
Published: (2019-07-01)

Hypersensitivity Reaction Associated with Abacavir Therapy in an Indian HIV Patient – A Case Report
by: MANJU JANARDHANAN, et al.
Published: (2014-09-01)

Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report
by: Mathew K. Koech, et al.
Published: (2022-11-01)

Low frequency of hypersensitivity reactions to abacavir in HIV infected patients in a referral center in Bahia, Brazil
by: Raphael Gusmão Barreto, et al.
Published: (2019-07-01)

Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.
by: Ward De Spiegelaere, et al.
Published: (2015-01-01)

Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis
by: Wimonchat Tangamornsuksan, et al.
Published: (2015-02-01)

Abacavir use is associated with increased prothrombin conversion
by: Qiuting Yan, et al.
Published: (2023-04-01)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study
by: Karam Mounzer, et al.
Published: (2019-01-01)

Abacavir-induced liver toxicity
by: Maria Diletta Pezzani, et al.
Published: (2016-09-01)

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
by: Green, H, et al.
Published: (2007)

Abacavir methanol 2.5-solvate
by: Phuong-Truc T. Pham
Published: (2009-08-01)

Relaxation effect of abacavir on rat basilar arteries.
by: Rachel Wai Sum Li, et al.
Published: (2015-01-01)

AOP-Based Transformation of Abacavir in Different Environments: Evolution Profile of Descyclopropyl-Abacavir and In Silico Toxicity Assessment of the Main Transformation Products
by: Eleni Evgenidou, et al.
Published: (2023-02-01)

Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment
by: Jianxiong Chan, et al.
Published: (2019-08-01)

Abacavir/lamivudine combination in the treatment of HIV: a review
by: Geetha Sivasubramanian, et al.
Published: (2010-02-01)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
by: Catherine Butkus Small, et al.
Published: (2017-04-01)

Comparison of Chemical and Electrochemical Approaches to Abacavir Oxidative Stability Testing
by: Lucie Pražáková, et al.
Published: (2023-03-01)

Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects
by: Eline Gall, et al.
Published: (2022-03-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011-06-01)

Abacavir-reactive memory T cells are present in drug naïve individuals.
by: Andrew Lucas, et al.
Published: (2015-01-01)

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
by: Lanier, E, et al.
Published: (2004)

Abacavir antiretroviral therapy and indices of subclinical vascular disease in persons with HIV.
by: Claudia A Martinez, et al.
Published: (2022-01-01)

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
by: Gibb, D, et al.
Published: (2002)

Approaches to tenofovir and abacavir drug shortages in South Africa: A guide for clinicians
by: Laurie Schowalter, et al.
Published: (2012-06-01)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
by: Julián Olalla, et al.
Published: (2018-10-01)

The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines.
by: Francesca Carlini, et al.
Published: (2010-01-01)

Immune reconstitution inflammatory syndrome in children
by: Helena Rabie, et al.
Published: (2009-12-01)

Kinetics of abacavir-induced remodelling of the major histocompatibility complex class I peptide repertoire
by: Illing, PT, et al.
Published: (2021)

Comparison of electrochemical and chemical approaches to forced oxidative degradation studies: Abacavir case study
by: Filip Vymyslický, et al.
Published: (2024-01-01)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
by: Langdahl Bente L, et al.
Published: (2011-10-01)

Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire
by: Patricia T. Illing, et al.
Published: (2021-05-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
by: Allison Martin, et al.
Published: (2011-01-01)

Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial
by: Musiime, V, et al.
Published: (2016)

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States
by: Kunchok Dorjee, et al.
Published: (2021-09-01)

Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity
by: Takeshi Susukida, et al.
Published: (2021-09-01)

Estimated use of abacavir among adults and children enrolled in public sector antiretroviral therapy programmes in Gauteng, South Africa
by: D Evans, et al.
Published: (2012-08-01)

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
by: Wolf E, et al.
Published: (2010-04-01)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2012-01-01)

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
by: Wolbers, M, et al.
Published: (2007)

Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
by: LePrevost, M, et al.
Published: (2006)